Brokerages Anticipate Humana Inc (HUM) Will Post Quarterly Sales of $13.91 Billion

Analysts expect that Humana Inc (NYSE:HUM) will report sales of $13.91 billion for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Humana’s earnings. The lowest sales estimate is $13.74 billion and the highest is $14.12 billion. Humana posted sales of $13.19 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.5%. The company is scheduled to report its next quarterly earnings report before the market opens on Wednesday, February 6th.

On average, analysts expect that Humana will report full year sales of $56.52 billion for the current financial year, with estimates ranging from $56.13 billion to $56.86 billion. For the next year, analysts forecast that the company will post sales of $61.14 billion, with estimates ranging from $60.38 billion to $61.98 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Humana.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same quarter in the previous year, the company earned $3.39 EPS.

A number of equities research analysts have recently commented on the stock. upped their price objective on shares of Humana from $350.00 to $373.00 and gave the company an “outperform” rating in a research note on Thursday, November 8th. Stephens started coverage on shares of Humana in a research report on Monday, January 14th. They set an “overweight” rating and a $336.00 price target for the company. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. Jefferies Financial Group increased their target price on shares of Humana from $388.00 to $410.00 and gave the stock a “buy” rating in a research report on Thursday, November 8th. Finally, Cowen upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $275.02 price objective for the company in a research report on Friday, January 11th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $348.85.

In other Humana news, Director David A. Jr/Ky Jones sold 600 shares of the business’s stock in a transaction on Saturday, November 16th. The stock was sold at an average price of $88.05, for a total transaction of $52,830.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Heidi S. Margulis sold 2,656 shares of Humana stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $296.22, for a total value of $786,760.32. Following the completion of the sale, the insider now owns 10,371 shares in the company, valued at approximately $3,072,097.62. The disclosure for this sale can be found here. In the last three months, insiders sold 9,078 shares of company stock valued at $2,570,350. Corporate insiders own 0.60% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Moody National Bank Trust Division purchased a new position in shares of Humana during the 4th quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Humana during the fourth quarter worth $57,000. Matthew Goff Investment Advisor LLC acquired a new stake in shares of Humana during the third quarter worth $64,000. IMS Capital Management acquired a new position in Humana in the third quarter valued at $68,000. Finally, Quadrant Capital Group LLC boosted its holdings in Humana by 24.6% in the fourth quarter. Quadrant Capital Group LLC now owns 365 shares of the insurance provider’s stock valued at $92,000 after acquiring an additional 72 shares during the last quarter. 92.72% of the stock is owned by hedge funds and other institutional investors.

HUM traded up $3.26 during trading on Friday, reaching $298.82. 55,286 shares of the company’s stock were exchanged, compared to its average volume of 910,399. Humana has a one year low of $260.00 and a one year high of $355.88. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.68 and a quick ratio of 1.68. The firm has a market capitalization of $40.55 billion, a price-to-earnings ratio of 25.52, a PEG ratio of 1.15 and a beta of 1.09.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s payout ratio is 8.54%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: Earnings Per Share

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.

Leave a Reply